Silenseed Ltd. followed hot on the heels of Vascular Biogenics Ltd. (VBL) to become the fourth Israeli biotech this year to seek a listing on a U.S. exchange. Filing as an emerging growth company, Silenseed is seeking to raise up to $36.4 million in its initial public offering (IPO) and to list on Nasdaq as RNAI.